Skinfold thickness and long-term post-menopausal hormone therapy.
Skinfold thickness was measured in 130 post-menopausal women treated with long-term hormone therapy. One group of 50 women took oestradiol valerate 2 mg/day for 3 wk out of 7, a second group comprising 19 women received oestriol succinate 2 mg/day and the remaining group of 61 women used oestradiol valerate 2 mg/day combined sequentially with norgestrel 0.5 mg/day. The duration of treatment in these groups was 6.3 +/- 0.4, 6.4 +/- 0.4 and 3.3 +/- 0.3 yr, respectively. The control group was made up of a further 89 post-menopausal women. The skinfold thickness in all the treated groups was significantly greater than that in the controls.
D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004964:Estriol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009644:Norgestrel / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects; D012885:Skinfold Thickness; D013997:Time Factors
D004967:Estrogens; D009644:Norgestrel; D004958:Estradiol; C009341:estriol succinate; D004964:Estriol